Mexdagry (Metformin Hydrochloride, Dapagliflozin)

Mexdagry combines metformin and dapagliflozin to target hyperglycemia in type 2 diabetes mellitus.

• Initial therapy in type 2 diabetes mellitus: improves glycemic control as part of first‑line treatment together with diet and exercise.
• Add‑on therapy for type 2 diabetes mellitus: provides additional glucose lowering when metformin alone does not achieve target HbA1c.
• Combination therapy with other antidiabetic agents: can be used alongside insulin or other oral agents to further reduce blood glucose levels.

• Metformin lowers hepatic glucose production and enhances peripheral insulin sensitivity by activating AMP‑activated protein kinase, while dapagliflozin blocks the renal sodium‑glucose co‑transporter‑2, reducing glucose reabsorption and increasing urinary glucose excretion. These mechanisms operate independently of insulin secretion, allowing the combination to be effective across a broad range of patients with varying degrees of beta‑cell function.

Common adverse reactions and rare serious events have been reported with the metformin/dapagliflozin combination.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
• Genital mycotic infection: increased risk of yeast infections in both sexes.
• Urinary tract infection: symptoms such as dysuria or increased frequency.
• Increased urinary volume: polyuria leading to mild dehydration.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic complication.
• Ketoacidosis: euglycemic diabetic ketoacidosis may occur.
• Severe dehydration or hypotension: especially in patients with renal impairment.
• Hypoglycemia: particularly when combined with insulin or sulfonylureas.

Before initiating Mexdagry, clinicians should evaluate several safety considerations.

• Renal function assessment: confirm eGFR meets the minimum requirement for both components.
• Lactic acidosis risk: avoid in patients with hepatic impairment, alcohol abuse, or conditions predisposing to hypoxia.
• Hypoglycemia monitoring: adjust doses of concomitant insulin or sulfonylureas to prevent low blood glucose.
• Genital infection vigilance: advise patients on proper genital hygiene to reduce infection risk.
• Pregnancy and lactation: use only if potential benefits justify potential risks to the fetus or infant.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Mexdagry may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Insulin or sulfonylureas: increased risk of hypoglycemia.
• IV contrast agents: may precipitate acute kidney injury; consider temporary discontinuation of metformin.
• Cimetidine: can raise dapagliflozin plasma concentrations.
• Diuretics: may exacerbate dehydration and hypotension.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: monitor renal function and electrolytes.
• NSAIDs: may affect renal clearance and increase risk of kidney injury.
• Alcohol: can potentiate metformin‑associated lactic acidosis.